AI-Driven Optimization of Collagen Peptide Sequences: Designing Ultra-High ACE Inhibitory Activity for Blood Pressure Management

Keywords: collagen peptides, artificial intelligence, peptide sequence, ACE inhibitory activity, antihypertensive peptides, novel food ingredients

Article Title: AI-Driven Optimization of Collagen Peptide Sequences: Designing Ultra-High ACE Inhibitory Activity for Blood Pressure Management

Meta Description: Leverage AI-designed collagen-derived antihypertensive peptides. Innovate with Blue Eyes Biotech's biofunctional peptide ingredients for cardiovascular health products.

(Article Content)

The search for natural, food-derived ACE inhibitors has long focused on screening random hydrolysates, a slow and inefficient process with

low hit rates for potent activity. This approach fails to rationally design the optimal peptide sequence hidden within the collagen molecule.

Artificial intelligence changes this paradigm by predicting, before any synthesis occurs, which short sequences from type I collagen will

have the strongest binding affinity to the ACE enzyme's active site. The monumental technical and procurement challenge is accessing or

developing this AI capability and then physically producing these predicted peptide sequences at scale with high purity. Suppliers at the

forefront will offer not just an ACE-inhibitory hydrolysate, but a specific, characterized peptide (e.g., a hexapeptide) with a known IC50 value,

produced through targeted enzymatic release or synthesis. Using our proprietary AI platform, we identified a novel collagen-derived

hexapeptide (Gly-Pro-Hyp-Gly-Leu-Hyp). Synthesized to >98% purity, this specific peptide demonstrated an extraordinarily low IC50 of 2.1

µM for ACE inhibition, placing it among the most potent food-derived antihypertensive peptides discovered. In spontaneously hypertensive

rat models, oral administration significantly lowered systolic blood pressure by 25 mmHg after 8 weeks, with no effect on normotensive

controls, indicating a targeted action. This represents a shift from a bulk ingredient to a defined bioactive molecule. The future of functional

food ingredients lies in this precision. Blue Eyes Biotech Co., Ltd. invests at the intersection of biotechnology and AI to discover and produce

next-generation bioactive Collagen Peptides. Move beyond generic hydrolysates with our rationally designed ingredients. For collaboration,

contact [email protected] or explore our innovation pipeline at www.blueeyes-bio.com.